MicroRNA-26a regulates glucose metabolism by direct targeting PDHX in colorectal cancer cells

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Chen, Bing ^a   Liu, Yuling ^a   Jin, Xuewen ^a   Lu, Weiliang ^a   Liu, Jingjing ^a   Xia, Zijing ^a   Yuan, Qiong ^b,c   Zhao, Xia ^a,c   Xu, Ningzhi ^d   Liang, Shufang ^a  

^a SICHUAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^d INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

Colorectal cancer; Glucose metabolism; MicroRNA 26a; PDHX

Indexed keywords

ACETYL COENZYME A; GLUCOSE; LACTIC ACID; MICRORNA 26A; PYRUVATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE PROTEIN X COMPONENT; PYRUVIC ACID; UNCLASSIFIED DRUG; MESSENGER RNA; MICRORNA; MIRN26A MICRORNA, HUMAN; PDHX PROTEIN, HUMAN; PYRUVATE DEHYDROGENASE COMPLEX;

3' UNTRANSLATED REGION; ARTICLE; BINDING SITE; BIOINFORMATICS; CANCER CELL; CANCER CELL LINE; CANCER INHIBITION; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; GLUCOSE INTAKE; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; NUCLEOTIDE SEQUENCE; PDHX GENE; PREDICTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA BINDING; WESTERN BLOTTING; BIOLOGY; BIOSYNTHESIS; CHEMISTRY; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; HCT116 CELL LINE; METABOLISM; RNA INTERFERENCE; TUMOR CELL LINE;

BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; COMPUTATIONAL BIOLOGY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE; HCT116 CELLS; HUMANS; LACTIC ACID; MICRORNAS; PYRUVATE DEHYDROGENASE COMPLEX; RNA INTERFERENCE; RNA, MESSENGER;

EID: 84903211634     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-443     Document Type: Article

References (42)

1. Chen B, Li H, Zeng X, Yang P, Liu X, Zhao X, Liang S. Roles of microRNA on cancer cell metabolism. J Transl Med 2012, 10(1):228. 10.1186/1479-5876-10-228, 3563491, 23164426.
2. Pucci S, Mazzarelli P. MicroRNA dysregulation in colon cancer microenvironment interactions: the importance of small things in metastases. Cancer Microenviron 2011, 4(2):155-162. 10.1007/s12307-011-0062-y, 3170419,3170419, 21909877.
3. Fang R, Xiao T, Fang Z, Sun Y, Li F, Gao Y, Feng Y, Li L, Wang Y, Liu X, Chen H, Liu X, Ji H. MicroRNA-143 (miR-143) regulates cancer glycolysis via targeting hexokinase 2 gene. J Biol Chem 2012, 287(27):23227-23235. 10.1074/jbc.M112.373084, 3391126, 22593586.
4. Singh PK, Brand RE, Mehla K. MicroRNAs in pancreatic cancer metabolism. Nat Rev Gastroenterol Hepatol 2012, 9(6):334-344. 10.1038/nrgastro.2012.63, 4045488, 22508159.
5. Fei X, Qi M, Wu B, Song Y, Wang Y, Li T. MicroRNA-195-5p suppresses glucose uptake and proliferation of human bladder cancer T24 cells by regulating GLUT3 expression. FEBS Lett 2012, 586(4):392-397. 10.1016/j.febslet.2012.01.006, 22265971.
6. Peschiaroli A, Giacobbe A, Formosa A, Markert EK, Bongiorno-Borbone L, Levine AJ, Candi E, D'Alessandro A, Zolla L, Finazzi Agro A, Melino G. miR-143 regulates hexokinase 2 expression in cancer cells. Oncogene 2013, 32(6):797-802. 10.1038/onc.2012.100, 22469988.
7. Jordan SD, Krüger M, Willmes DM, Redemann N, Wunderlich FT, Brönneke HS, Merkwirth C, Kashkar H, Olkkonen VM, Böttger T, Braun T, Seibler J, Brüning JC. Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nat Cell Biol 2011, 13(4):434-446. 10.1038/ncb2211, 21441927.
8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674. 10.1016/j.cell.2011.02.013, 21376230.
9. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011, 11(2):85-95. 10.1038/nrc2981, 21258394.
10. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006, 103(7):2257-2261. 10.1073/pnas.0510565103, 1413718, 16461460.
11. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, Davuluri R, Liu CG, Croce CM, Negrini M, Calin GA, Ivan M. A microRNA signature of hypoxia. Mol Cell Biol 2007, 27(5):1859-1867. 10.1128/MCB.01395-06, 1820461, 17194750.
12. Zhang B, Liu XX, He JR, Zhou CX, Guo M, He M, Li MF, Chen GQ, Zhao Q. Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis 2011, 32(1):2-9. 10.1093/carcin/bgq209, 20952513.
13. Chen L, Zheng J, Zhang Y, Yang L, Wang J, Ni J, Cui D, Yu C, Cai Z. Tumor-specific expression of microRNA-26a suppresses human hepatocellular carcinoma growth via cyclin-dependent and -independent pathways. Mol Ther 2011, 19(8):1521-1528. 10.1038/mt.2011.64, 3149175, 21610700.
14. Leeper NJ, Raiesdana A, Kojima Y, Chun HJ, Azuma J, Maegdefessel L, Kundu RK, Quertermous T, Tsao PS, Spin JM. MicroRNA-26a is a novel regulator of vascular smooth muscle cell function. J Cell Physiol 2011, 226(4):1035-1043. 10.1002/jcp.22422, 3108574, 20857419.
15. Liu B, Wu X, Wang C, Liu Y, Zhou Q, Xu K. MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN. Biochim Biophys Acta 2012, 1822(11):1692-1704. 10.1016/j.bbadis.2012.07.019, 22885155.
16. Altenberg B, Greulich KO. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 2004, 84(6):1014-1020. 10.1016/j.ygeno.2004.08.010, 15533718.
17. Alcarraz-Vizan G, Sanchez-Tena S, Moyer MP, Cascante M. Validation of NCM460 cell model as control in antitumor strategies targeting colon adenocarcinoma metabolic reprogramming: Trichostatin A as a case study. Biochim Biophys Acta 2013, 1840(6):1634-1639.
18. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N. Combinatorial microRNA target predictions. Nat Genet 2005, 37(5):495-500. 10.1038/ng1536, 15806104.
19. Jiang S, Zhang LF, Zhang HW, Hu S, Lu MH, Liang S, Li B, Li Y, Li D, Wang ED, Liu MF. A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. EMBO J 2012, 31(8):1985-1998. 10.1038/emboj.2012.45, 3343331, 22354042.
20. Sze CW, Li C. Inactivation of bb0184, which encodes carbon storage regulator A, represses the infectivity of Borrelia burgdorferi. Infect Immun 2011, 79(3):1270-1279. 10.1128/IAI.00871-10, 3067481, 21173314.
21. Moyer MP, Manzano LA, Merriman RL, Stauffer JS, Tanzer LR. NCM460, a normal human colon mucosal epithelial cell line. In Vitro Cell Dev Biol Anim 1996, 32(6):315-317. 10.1007/BF02722955, 8842743.
22. Bhattacharyya NP, Skandalis A, Ganesh A, Groden J, Meuth M. Mutator phenotypes in human colorectal carcinoma cell lines. Proc Natl Acad Sci U S A 1994, 91(14):6319-6323. 10.1073/pnas.91.14.6319, 44193, 8022779.
23. Xue H, Lü B, Zhang J, Wu M, Huang Q, Wu Q, Sheng H, Wu D, Hu J, Lai M. Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. J Proteome Res 2009, 9(1):545-555.
24. Tajir M, Arnoux JB, Boutron A, Elalaoui SC, De Lonlay P, Sefiani A, Brivet M. Pyruvate dehydrogenase deficiency caused by a new mutation of PDHX gene in two Moroccan patients. Eur J Med Genet 2012, 55(10):535-540. 10.1016/j.ejmg.2012.06.006, 22766002.
25. Mine M, Brivet M, Schiff M, de Baulny HO, Chuzhanova N, Marsac C. A novel gross deletion caused by non-homologous recombination of the PDHX gene in a patient with pyruvate dehydrogenase deficiency. Mol Genet Metab 2006, 89(1-2):106-110.
26. Huse JT, Brennan C, Hambardzumyan D, Wee B, Pena J, Rouhanifard SH, Sohn-Lee C, le Sage C, Agami R, Tuschl T, Holland EC. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev 2009, 23(11):1327-1337. 10.1101/gad.1777409, 2701585, 19487573.
27. Yang X, Liang L, Zhang XF, Jia HL, Qin Y, Zhu XC, Gao XM, Qiao P, Zheng Y, Sheng YY, Wei JW, Zhou HJ, Ren N, Ye QH, Dong QZ, Qin LX. MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology 2013, 58(1):158-170. 10.1002/hep.26305, 23389848.
28. Stacpoole PW. The pyruvate dehydrogenase complex as a therapeutic target for age-related diseases. Aging Cell 2012, 11:371-377. 10.1111/j.1474-9726.2012.00805.x, 22321732.
29. Margineantu DH, Brown RM, Brown GK, Marcus AH, Capaldi RA. Heterogeneous distribution of pyruvate dehydrogenase in the matrix of mitochondria. Mitochondrion 2002, 1(4):327-338. 10.1016/S1567-7249(01)00033-2, 16120287.
30. Thorens B, Mueckler M. Glucose transporters in the 21st century. Am J Physiol Endocrinol Metab 2010, 298:E141-E145. 10.1152/ajpendo.00712.2009, 2822486, 20009031.
31. Fiaschi T, Marini A, Giannoni E, Taddei M, Gandellini P, De Donatis A, Lanciotti M, Serni S, Cirri P, Chiarugi P. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Res 2012, 72:5130-5140. 10.1158/0008-5472.CAN-12-1949, 22850421.
32. Fiaschi T, Giannoni E, Taddei M, Cirri P, Marini A, Pintus G, Nativi C, Richichi B, Scozzafava A, Carta F, Torre E, Supuran CT, Chiarugi P. Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle 2013, 12:1791-1801. 10.4161/cc.24902, 3713137, 23656776.
33. Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol 2012, 6(6):590-610. 10.1016/j.molonc.2012.09.006, 23102669.
34. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S, Orum H. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010, 327(5962):198-201. 10.1126/science.1178178, 3436126, 19965718.
35. Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S. Inhibition of microRNA function by antimiR oligonucleotides. Silence 2012, 3(1):1. 10.1186/1758-907X-3-1, 3306207, 22230293.
36. Rossi JJ. New hope for a microRNA therapy for liver cancer. Cell 2009, 137(6):990-992. 10.1016/j.cell.2009.05.038, 19524500.
37. Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today 2013, 18(5-6):282-289.
38. El Ouaamari A, Baroukh N, Martens GA, Lebrun P, Pipeleers D, van Obberghen E. miR-375 targets 3′-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells. Diabetes 2008, 57(10):2708-2717. 10.2337/db07-1614, 2551681, 18591395.
39. Kluza J, Corazao-Rozas P, Touil Y, Jendoubi M, Maire C, Guerreschi P, Jonneaux A, Ballot C, Balayssac S, Valable S, Corroyer-Dulmont A, Bernaudin M, Malet-Martino M, de Lassalle EM, Maboudou P, Formstecher P, Polakowska R, Mortier L, Marchetti P. Inactivation of the HIF-1alpha/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants. Cancer Res 2012, 72(19):5035-5047. 10.1158/0008-5472.CAN-12-0979, 22865452.
40. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012, 4(3):143-159. 10.1002/emmm.201100209, 3376845, 22351564.
41. Boni V, Zarate R, Villa JC, Bandres E, Gomez MA, Maiello E, Garcia-Foncillas J, Aranda E. Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. Pharmacogenomics J 2011, 11(6):429-436. 10.1038/tpj.2010.58, 20585341.
42. Di Leva G, Briskin D, Croce CM. MicroRNA in cancer: new hopes for antineoplastic chemotherapy. Ups J Med Sci 2012, 117(2):202-216. 10.3109/03009734.2012.660551, 3339552, 22348396.